ReShape Lifesciences (NASDAQ:RSLS) Raised to Hold at Wall Street Zen

ReShape Lifesciences (NASDAQ:RSLS) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

ReShape Lifesciences Price Performance

Shares of ReShape Lifesciences stock opened at $4.76 on Friday. The business’s fifty day moving average price is $10.10 and its two-hundred day moving average price is $65.37. The company has a market capitalization of $3.51 million, a P/E ratio of -0.02 and a beta of 1.48. ReShape Lifesciences has a 1-year low of $4.74 and a 1-year high of $725.00.

ReShape Lifesciences (NASDAQ:RSLS) last announced its earnings results on Tuesday, May 20th. The medical device company reported $18.98 earnings per share for the quarter. The firm had revenue of $1.11 million for the quarter. ReShape Lifesciences had a negative return on equity of 179.83% and a negative net margin of 86.36%.

ReShape Lifesciences Company Profile

ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.